Overview

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Metformin
Saxagliptin